Forskolin: A promising new adjunct to intracavernous pharmacotherapy

David Cahn, Arnold Melman, Mira Valcic, George J. Christ

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: To evaluate the utility of forskolin as a potentially novel intracavernous therapy. Materials and Methods: Forskolin- and prostaglandin E1 (PGE1)-induced intracorporal pressure changes were evaluated in vivo by cavernosometry performed on 2 male mongrel dogs, while systemic pressure changes were simultaneously monitored. Forskolin- and PGE1-induced intracellular cAMP accumulation was measured in vitro on homogeneous explant cultures of canine corporal smooth muscle cells. Results: Forskolin and PGE1 elicited concentration-dependent increases in cAMP accumulation in cultured canine corporal smooth muscle cells. Forskolin and PGE1 also elicited concentration-dependent increases in both the magnitude and duration of intracorporal pressure, up to a maximum of 80 to 90% of mean arterial pressure. Furthermore, the presence of threshold concentrations of forskolin was shown to significantly augment the activity of PGE1 both in vitro (increased cAMP) and in vivo (increased pressure). Moreover, there were no detectable systemic effects following the intracorporal injection of forskolin or a mixture of forskolin and PGE1. Conclusions: These observations suggest that the use of forskolin, alone or in combination with other drugs that increase intracellular cAMP levels, might represent an attractive opportunity for improved and more rational development of next generation intracavernous pharmacotherapeutic agents.

Original languageEnglish (US)
Pages (from-to)1789-1794
Number of pages6
JournalJournal of Urology
Volume155
Issue number5
DOIs
StatePublished - May 1996

Fingerprint

Colforsin
Alprostadil
Drug Therapy
Pressure
Smooth Muscle Myocytes
Canidae
Arterial Pressure
Dogs
Injections

Keywords

  • cyclic AMP
  • forskolin
  • impotence

ASJC Scopus subject areas

  • Urology

Cite this

Forskolin : A promising new adjunct to intracavernous pharmacotherapy. / Cahn, David; Melman, Arnold; Valcic, Mira; Christ, George J.

In: Journal of Urology, Vol. 155, No. 5, 05.1996, p. 1789-1794.

Research output: Contribution to journalArticle

Cahn, David ; Melman, Arnold ; Valcic, Mira ; Christ, George J. / Forskolin : A promising new adjunct to intracavernous pharmacotherapy. In: Journal of Urology. 1996 ; Vol. 155, No. 5. pp. 1789-1794.
@article{ae966a43404349f68d9135862d5e2f61,
title = "Forskolin: A promising new adjunct to intracavernous pharmacotherapy",
abstract = "Purpose: To evaluate the utility of forskolin as a potentially novel intracavernous therapy. Materials and Methods: Forskolin- and prostaglandin E1 (PGE1)-induced intracorporal pressure changes were evaluated in vivo by cavernosometry performed on 2 male mongrel dogs, while systemic pressure changes were simultaneously monitored. Forskolin- and PGE1-induced intracellular cAMP accumulation was measured in vitro on homogeneous explant cultures of canine corporal smooth muscle cells. Results: Forskolin and PGE1 elicited concentration-dependent increases in cAMP accumulation in cultured canine corporal smooth muscle cells. Forskolin and PGE1 also elicited concentration-dependent increases in both the magnitude and duration of intracorporal pressure, up to a maximum of 80 to 90{\%} of mean arterial pressure. Furthermore, the presence of threshold concentrations of forskolin was shown to significantly augment the activity of PGE1 both in vitro (increased cAMP) and in vivo (increased pressure). Moreover, there were no detectable systemic effects following the intracorporal injection of forskolin or a mixture of forskolin and PGE1. Conclusions: These observations suggest that the use of forskolin, alone or in combination with other drugs that increase intracellular cAMP levels, might represent an attractive opportunity for improved and more rational development of next generation intracavernous pharmacotherapeutic agents.",
keywords = "cyclic AMP, forskolin, impotence",
author = "David Cahn and Arnold Melman and Mira Valcic and Christ, {George J.}",
year = "1996",
month = "5",
doi = "10.1016/S0022-5347(01)66199-8",
language = "English (US)",
volume = "155",
pages = "1789--1794",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Forskolin

T2 - A promising new adjunct to intracavernous pharmacotherapy

AU - Cahn, David

AU - Melman, Arnold

AU - Valcic, Mira

AU - Christ, George J.

PY - 1996/5

Y1 - 1996/5

N2 - Purpose: To evaluate the utility of forskolin as a potentially novel intracavernous therapy. Materials and Methods: Forskolin- and prostaglandin E1 (PGE1)-induced intracorporal pressure changes were evaluated in vivo by cavernosometry performed on 2 male mongrel dogs, while systemic pressure changes were simultaneously monitored. Forskolin- and PGE1-induced intracellular cAMP accumulation was measured in vitro on homogeneous explant cultures of canine corporal smooth muscle cells. Results: Forskolin and PGE1 elicited concentration-dependent increases in cAMP accumulation in cultured canine corporal smooth muscle cells. Forskolin and PGE1 also elicited concentration-dependent increases in both the magnitude and duration of intracorporal pressure, up to a maximum of 80 to 90% of mean arterial pressure. Furthermore, the presence of threshold concentrations of forskolin was shown to significantly augment the activity of PGE1 both in vitro (increased cAMP) and in vivo (increased pressure). Moreover, there were no detectable systemic effects following the intracorporal injection of forskolin or a mixture of forskolin and PGE1. Conclusions: These observations suggest that the use of forskolin, alone or in combination with other drugs that increase intracellular cAMP levels, might represent an attractive opportunity for improved and more rational development of next generation intracavernous pharmacotherapeutic agents.

AB - Purpose: To evaluate the utility of forskolin as a potentially novel intracavernous therapy. Materials and Methods: Forskolin- and prostaglandin E1 (PGE1)-induced intracorporal pressure changes were evaluated in vivo by cavernosometry performed on 2 male mongrel dogs, while systemic pressure changes were simultaneously monitored. Forskolin- and PGE1-induced intracellular cAMP accumulation was measured in vitro on homogeneous explant cultures of canine corporal smooth muscle cells. Results: Forskolin and PGE1 elicited concentration-dependent increases in cAMP accumulation in cultured canine corporal smooth muscle cells. Forskolin and PGE1 also elicited concentration-dependent increases in both the magnitude and duration of intracorporal pressure, up to a maximum of 80 to 90% of mean arterial pressure. Furthermore, the presence of threshold concentrations of forskolin was shown to significantly augment the activity of PGE1 both in vitro (increased cAMP) and in vivo (increased pressure). Moreover, there were no detectable systemic effects following the intracorporal injection of forskolin or a mixture of forskolin and PGE1. Conclusions: These observations suggest that the use of forskolin, alone or in combination with other drugs that increase intracellular cAMP levels, might represent an attractive opportunity for improved and more rational development of next generation intracavernous pharmacotherapeutic agents.

KW - cyclic AMP

KW - forskolin

KW - impotence

UR - http://www.scopus.com/inward/record.url?scp=0029967490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029967490&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)66199-8

DO - 10.1016/S0022-5347(01)66199-8

M3 - Article

C2 - 8627885

AN - SCOPUS:0029967490

VL - 155

SP - 1789

EP - 1794

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -